Skip to main content

PROCEDURA TRAMITE PORTALE MEPA PER LA FORNITURA DI REAGENTI NELL'AMBITO DEL PROGETTO BLOOD BIOMARKERS FOR ALZHEIMER'S DISEASE AND NEUROINJURY TO ESTIMATE THE ASSOCIATION WITH COGNITIVE/FUNCTIONAL DECLINE AND MORTALITY IN A REAL WORLD POPULATION OF GERIATRIC HOSPITALIZED PATIENTS: BAD-GER BIOMARKERS

IST.NAZ.LE DI RIPOSO E CURA PER ANZIANI VITT EMANUELE II

CIG B56E3B79C0Verify on ANACMarche · AnconaGoods / suppliesCompetitive dialogueCPV 33696500-0Near legal thresholdRisk signal — not an accusation of crime.
At a glance
Key figures from open ANAC records for this contract.

Amount

€145,409

Award date

9 May 2025

Bids

1

Published

30 Jan 2025

Estimated tender value

€145,410

Sector (CPV)

REATTIVI PER LABORATORIO
Timeline
  1. Publication / start of procedure

    30 Jan 2025

    Step completed
  2. Time to submit bids

    4 Feb 2025

    5 days between opening and deadline

    Step completed
  3. Award

    9 May 2025

In plain language

These are automated checks on public data. They help you decide what to look into — they are not criminal findings.

This contract triggered 4 pattern(s) worth a closer look:

Low competition · Tight deadlines

Contracting authority (buyer)
Awarded to (suppliers)
1 award line(s) on record.
SupplierRegionAmountAward dateStatus
BIO-TECHNE S.R.L.€145,4099 May 2025AGGIUDICATA
How do I verify this tender?

Loading actions…

Similar tenders in the same area

Loading comparison…

Sector comparison

Loading…

Amount vs category

Loading…

Citizen verifier notes
Share what you verified on official sources — not a verdict
How the score is built
Ruleset 2.0.0 · 5 Jul 2026
Source data & verification

ANAC BDNCP — dati tabellari

Verify on ANAC

Ingested: 27 Jun 2026

Release: cig_csv_2025_01

Days to submit bids: 5

PROCEDURA TRAMITE PORTALE MEPA PER LA FORNITURA DI REAGENTI NELL'AMBITO DEL PROGETTO BLOOD BIOMARKERS FOR ALZHEIMER'S DISEASE AND NEUROINJURY TO ESTIMATE THE ASSOCIATION WITH COGNITIVE/FUNCTIONAL DECLINE AND MORTALITY IN A REAL WORLD POPULATION OF GERIATRIC HOSPITALIZED PATIENTS: BAD-GER BIOMARKERS — AppaltiWatch